Skip Navigation

European Heart Journal 2000 21(10):790-792; doi:10.1053/euhj.1999.2069
Copyright © 2000 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Betteridge, D.J.
Right arrow Articles by Close, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Betteridge, D.J.
Right arrow Articles by Close, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Editorial

Diabetes, coronary heart disease and sulphonylureas—not the final word

D.J. Betteridge and L. Close

Royal Free University College Medical School, University College London, London, U.K.

References

  1. Diabetes. 1976;25:1129–1153[ISI][Medline]
  2. Engler RL, Yellon DM. Sulphonylurea KATPblockade in type II diabetes preconditioning in cardiovascular disease. Time for reconsideration. Circulation. 1996;94:2297–2301[Free Full Text]
  3. Brady PA, Terzic A. The sulphonylurea controversy: more questions from the heart. J Am Coll Cardiol. 1998;31:950–956[Abstract/Free Full Text]
  4. Klamman A, Sarfert P, Launhardt V, Schulte G, Schmiegel WH, Nauck MA. Myocardial infarction in diabetic vs non-diabetic subjects; survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J. 2000;21:220–229[Abstract/Free Full Text]
  5. Gribble FM, Tucker SJ, Seino S, Ashcroft FM. Tissue specificity of sulphonylureas. Studies on cloned cardiac and ß-cell KATPchannels. Diabetes. 1998;47:1412–1418[Abstract/Free Full Text]
  6. Klepzig H, Kober G, Mutter C. Sulphonylureas and ischaemic preconditioning. A double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur Heart J. 1999;20:439–446[Abstract/Free Full Text]
  7. Malmberg K. Br Med J. 1997;314:1512–1515[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 HeartHome page
Z S Kyriakides, S Psychari, N Chrysomallis, M Georgiadis, E Sbarouni, and D T Kremastinos
Type II diabetes does not prevent the recruitment of collateral vessels and the normal reduction of myocardial ischaemia on repeated balloon inflations during angioplasty
Heart, January 1, 2002; 87(1): 61 - 66.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
M. Weih, N. Amberger, S. Wegener, U. Dirnagl, T. Reuter, and K. Einhaupl
Sulfonylurea Drugs Do Not Influence Initial Stroke Severity and In-Hospital Outcome in Stroke Patients With Diabetes
Stroke, September 1, 2001; 32(9): 2029 - 2032.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (5)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Betteridge, D.J.
Right arrow Articles by Close, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Betteridge, D.J.
Right arrow Articles by Close, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?